What Caught Our Attention: Any time there’s an issue with a paper co-authored by researchers from such high-profile institutions as Harvard, Cornell, and the University of Cambridge, we take notice. In this case, the group — which included Laurie Glimcher, then-dean at Cornell, now president of the Dana-Farber Cancer Institute — chose to retract a 2013 paper from a Cell journal after learning they couldn’t reproduce some of the experiments. Continue reading Caught Our Notice: A team from Harvard, Cornell, Cambridge, HHMI, and UCSF can’t reproduce a paper’s findings
led to an incorrect conclusion in the paper that NADPH activity is elevated in Huntington’s disease (HD). Some original data were missing and efforts to replicate findings using the reported method or an alternative approach were unsuccessful. An institutional faculty panel supports the decision and the reasons for the retraction.
The notice added that the alleged data manipulation and fabrication affected bar graphs in two of the paper’s figures.
Terri Ogan, a spokesperson for Mass General, told Retraction Watch that Valencia no longer works at the institution, but declined to say whether there has been an investigation into the alleged misconduct: Continue reading Data fabrication by ex-Harvard researcher takes down paper on Huntington’s disease
Regular Retraction Watch readers may recall a remarkable story from January involving Harvard’s Lee Rubin and one of his graduate students. As we reported in Science at the time, the graduate student, Gustavo German, said he had been subjected to a forced psychiatric evaluation as “an act of revenge by Rubin, retaliation prompted by German’s allegation of scientific misconduct against Rubin and two of his students.” And a judge “agreed with German, concluding [last August] that Rubin was ‘motivated by bias and revenge, not by a legitimate interest in keeping German safe.'”
That led to a restraining order that required Rubin to remain 100 feet from German at all times — including in the lab where German was working on his PhD.
Today, we have an update on the story, also in Science: “At Harvard, extraordinary court battle between Ph.D. student and prominent researcher grinds on.” As our Alison McCook writes: Continue reading The Harvard lab head, the grad student, and the restraining order: An ongoing saga
Late last year, Carl Ronald Kahn—also chief academic officer at Joslin Diabetes Center—retracted two papers for similar reasons. In November, Kahn pulled a 2005 paper from The Journal of Clinical Investigation (JCI) and a month later, he retracted a 2003 paper from The Journal of Biological Chemistry (JBC), both times citing duplications that the authors said were introduced while assembling the figures.
Last month, Kahn retracted his third paper, also published in JBC in 2003, because the authors omitted data when constructing the images. Still, the authors remain confident in their findings, given that data from other labs “have confirmed and extended the conclusions of the manuscript.”
The former president of the Joslin Diabetes Center has withdrawn a second article within a month of his first, and issued extensive corrections to another paper in the same journal, all due to figure errors.
In November, we reported that Carl Ronald Kahn — also affiliated with Harvard Medical School — had pulled a highly cited 2005 paper from The Journal of Clinical Investigation because of image duplication issues, which Kahn told us were introduced during figure assembly. This December, Kahn retracted a 2003 paper published in The Journal of Biological Chemistry (JBC)—again due to duplication issues that the authors believe “were inadvertently introduced during figure assembly.”
Here’s the retraction notice for “Bi-directional regulation of brown fat adipogenesis by the insulin receptor,” cited 46 times, according to Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters:
Last March, a PhD student at Harvard filed a misconduct allegation against his mentor, a prominent stem cell researcher. Three months later, he was taken from his home by police in the middle of the night for a forced psychiatric evaluation.
Retraction Watch readers may recall the case of Piero Anversa and Annarosa Leri, both formerly of Harvard and the Brigham & Women’s Hospital in Boston. The pair — which has had their work subjected to a retraction, expression of concern, and correction — sued their former employers in 2014 for costing them job offers after the institutions notified journals, triggering notices. A judge dismissed the case a year ago, saying that Anversa and Leri had to try other administrative remedies before bringing suit.
But Anversa and Leri appealed, and last week, a court denied that appeal. (See the judge’s decision — which begins by quoting Ecclesiastes and includes the delicious word “gallimaufry” — here.) We spoke by email to two attorneys — Richard Goldstein, who represented the scientist in Bois v. HHS, the first case to overturn a funding ban by the Office of Research Integrity (ORI), and Paul Thaler, who has represented scientists involved in misconduct proceedings for more than 25 years — about the case, and what it could mean for similar lawsuits.
Retraction Watch: The decision seems to stop Anversa and Leri from continuing their suit against Harvard and the Brigham, but also acknowledges some of the scientists’ concerns as legitimate. How would you summarize the findings and their implications? Continue reading Scientists investigated for misconduct lose appeal in suit against Harvard. Lawyers explain what it means.
Rather, the Journal of Mammary Gland Biology and Neoplasia decided to retract the paper because it referenced other papers that had been retracted as a result of data manipulation.
The notice doesn’t specify which references were problematic, but the list includes three papers that are now retracted; all three include Scott Valastyan (the sole author of the newly retracted paper) as first author, and two list Robert Weinberg, his former supervisor and prominent cancer researcher, as last author.
What the Harvard Theological Review giveth, it evidently will not taketh away.
The venerable publication about religious matters is refusing to retract a 2014 article by a noted scholar of early Christianity despite evidence that the article — about Jesus’s wife — was based on a forgery.
The paper, by Harvard theologian Karen King, described a Coptic papyrus called “The Gospel of Jesus’s Wife,” which, among other things, includes language that suggests Christ was married: Continue reading Coptic cop-out? Religion journal won’t pull paper based on bogus ‘gospel’
After an investigation found evidence of misconduct, a biologist has issued a third retraction.
Sudarsanareddy Lokireddy — now a research fellow at Harvard Medical School — “admitted falsification,” a Research Integrity Officer at Nanyang Technological University in Singapore told us in December. According to The Scientist, another journal has also published a correction that the authors had requested earlier.
The newly retracted paper is “Myostatin is a novel tumoral factor that induces cancer cachexia,” published in Biochemical Journal and cited 40 times, according to Thomson Reuters Web of Science. Here’s the retraction note: